Carli F, Brambilla A, Di Rella M, Frattini C, Brandt A
Vectorpharma International S.p.A., Trieste.
Boll Chim Farm. 1996 Jan;135(1):12-4.
Ursodeoxycholic acid, like all weak acids, has to be formulated so as his release and absorption depend as little as possible by the pH of gastrointestinal tract. To obtain this result a controlled release formulation of UDCA was developed, based on bioadhesive technique. This allowed a longer residence and absorption time of the active ingredient both at gastric (due to gastrosoluble rate) and duodenal-jejunum level (gastroresistant rate). Thus, all the absorption windows for bile acids are utilized, to ameliorate the total bioavailability of the drug.
熊去氧胆酸与所有弱酸一样,必须进行制剂设计,使其释放和吸收尽可能少地受胃肠道pH值的影响。为了达到这一效果,基于生物黏附技术开发了熊去氧胆酸的控释制剂。这使得活性成分在胃部(由于胃溶速率)和十二指肠-空肠水平(胃抗速率)都有更长的驻留和吸收时间。因此,胆汁酸的所有吸收窗口都得到了利用,以提高药物的总生物利用度。